New Technology Provides Sustained Relief for Managing Chronic Condition

Richmond, VA– February 21, 2018 – Virginia Ear Nose & Throat is among the first in the United States to offer a new technology recently approved by the FDA to treat nasal polyps in adults who have had previous ethmoid sinus surgery (ESS).

Nasal polyps are inflammatory growths along the lining of the nasal passages that can occur in patients suffering from chronic sinusitis. The symptoms of chronic sinusitis include nasal discharge, congestion, facial pain, and a loss of sense of smell. Many people return to their ENT specialist with recurring polyps even after undergoing previous ethmoid sinus surgery.1

Virginia Ear Nose & Throat now offers Intersect ENT’s SINUVA Sinus Implant, placed during a routine physician office visit. SINUVA expands in the sinus cavity, delivering a steroid directly to the sinus for up to 90 days. SINUVA softens over time and can be removed at 90 days or earlier at the physician’s discretion.

1 Wynn, R. and G. Har-El (2004). "Recurrence rates after endoscopic sinus surgery for massive sinus polyposis." Laryngoscope 114(5): 811-813.

“Many people suffer from recurrent nasal polyps, a debilitating condition that can greatly affect a person’s life,” says Dr. Robert J. Brager of Virginia ENT.  "Until now, existing treatments have included repeat surgery, high-dose oral steroids, or intranasal sprays that require ongoing patient compliance. We are very excited to be among the first in the U.S. to offer this innovative treatment choice to our patients.”

Positive data from SINUVA™ Sinus Implant was supported by results of the RESOLVE II pivotal study.  The study demonstrated a reduction in polyps, nasal obstruction/congestion, a reduction in need for repeat sinus surgery, and an improvement in impaired sense of smell.2
To learn more about SINUVA, visit SINUVA.com. To see full prescribing information, click here.

2 Data on file, Intersect ENT. RESOLVE II CSR R 28017 Rev. 3.0 February 2017